IDEXX Laboratories, Inc.

NASDAQ:IDXX

Medical - Diagnostics & Research

Healthcare
$698.47 +2.26%

+$12.33 today

Market cap
$55.03B
Beta
1.54
P/E (TTM)
40.8
EPS (TTM)
$13.67
52W Low $506.91High $769.98

Volume 0.37M

Average 0.58M

IDXX Interest Income

Income earned on cash, deposits, and investments held by the company.

IDEXX Laboratories, Inc.NASDAQ: IDXX

Interest Income · Q3 FY2026 · quarter ended Sep 2026

Interest income remains negative

Q3 FY2026 interest income was $0, compared with $580K a year earlier. Trailing-twelve-month interest income was $1.79M. Over 3 fiscal years it compounded at +31.5% a year.

Context

  • Interest income amounted to 0.1% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $447.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$2.42M-80.9% YoY
LTMSep 2026
$1.79M-61.3% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-80.9%——
3-year CAGR+31.5%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
2.42M USD
Year-over-year change
-80.9%
4-year CAGR
+53.7%

Interest Income vs competitors

How IDXX compares with its peers on the latest reported figures

  • IDXX's LTM Sep 2026 interest income of $1.79M is the 4th highest of the 5 companies compared; the peer median is $41.5M.
  • Its year-over-year change of -61.3% is the 4th highest of 5, against a peer median of -38.7%.
  • Interest income amounts to 0.0% of revenue for IDXX, versus a peer median of 0.3%.
IDXX Competitors Peer median
Interest Income for IDXX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$200M -55.7%+29.8%0.3%
ZTSZoetis Inc.LTM Jun 2026$72M -21.7%+23.0%0.8%
ELANElanco Animal Health IncorporatedLTM Sep 2026$11M +0.0%—0.2%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$1.79M -61.3%+31.5%0.0%
NEOGNeogen CorporationLTM Aug 2026$592K -80.5%—0.1%
Peer median (excluding IDXX) $41.5M-38.7%+26.4%0.3%

Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.22B3.37B3.66B3.9B4.3B
Cost of Revenue1.33B1.36B1.47B1.52B1.64B
Gross Profit1.89B2B2.19B2.38B2.66B
Gross Margin58.8%59.5%59.8%61.0%61.8%
Research & Development161.01M254.82M190.95M219.79M251.21M
Selling, General & Admin796.4M850.75M901.89M1.03B1.05B
Operating Expenses957.4M1.11B1.09B1.25B1.3B
Depreciation & Amortization104.6M111.9M114.91M129.94M145.18M
EBITDA1.04B1.01B1.22B1.28B1.51B
EBITDA Margin32.3%30.1%33.3%32.7%35.0%
Operating Income932.03M898.77M1.1B1.13B1.36B
Operating Margin29.0%26.7%30.0%29.0%31.6%
Interest Income434K1.07M5.63M12.7M2.42M
Interest Expense29.81M39.86M41.58M31.21M38.27M
Other Income / Expenses(29.37M)(38.79M)(35.95M)(18.51M)(35.84M)
Income Before Tax902.65M859.97M1.06B1.11B1.32B
Pre-Tax Margin28.1%25.5%29.0%28.5%30.8%
Income Tax Expense157.81M180.88M216.13M221.96M264.73M
Net Income744.85M679.09M845.04M887.87M1.06B
Net Margin23.2%20.2%23.1%22.8%24.6%
EPS (Basic)8.748.1210.1710.7713.17
EPS (Diluted)8.608.0310.0610.6713.08
Weighted Avg Shares85.2M83.62M83.07M82.47M80.1M
Weighted Avg Shares (Diluted)86.57M84.6M83.98M83.25M80.68M

IDEXX Laboratories, Inc.

NASDAQ:IDXX

Intrinsic Alpha fair value

Locked

Current Price

$698.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.